Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2093587 | 0.81 | LMNA (0.61) | LMNAHPGDSMN1; SMN2NLRP3POLB | |
| SCHEMBL2093582 | 0.79 | LMNA (0.59) | LMNAHPGDSMN1; SMN2NLRP3POLB | |
| SCHEMBL23177820 | 0.77 | L3MBTL1 (0.79) | LMNAL3MBTL1HPGDPOLBMEN1 | |
| SCHEMBL28796266 | 0.77 | LMNA (0.56) | LMNAHPGDSMN1; SMN2NLRP3POLB | |
| SCHEMBL2092062 | 0.76 | LMNA (0.69) | LMNAL3MBTL1HPGDNLRP3POLB | |
| SCHEMBL2092059 | 0.74 | LMNA (0.67) | LMNAL3MBTL1HPGDNLRP3POLB | |
| SCHEMBL12883186 | 0.74 | TSHR (0.77) | LMNAL3MBTL1HPGDNLRP3POLB | |
| SCHEMBL3131919 | 0.74 | LCK (0.60) | LMNAL3MBTL1NLRP3ALDH1A1 | |
| SCHEMBL11578854 | 0.73 | LMNA (0.70) | LMNAL3MBTL1HPGDPOLBMEN1 | |
| SCHEMBL3899409 | 0.73 | LMNA (0.96) | LMNAL3MBTL1HPGDNLRP3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | WASE, NISHIKANT | 2020-03-05 | — | — | US | disclosed |
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | NUTECH VENTURES (US) | 2019-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351883-B2 | Compounds for increasing lipid synthesis and storage | FASN, LIPC, SREBF2 | LMNA 966/4885L3MBTL1 2703/4885HPGD 610/4885 |
| US-20200071735-A1 | Compounds for Increasing Lipid Synthesis and Storage | FASN, LIPC, SREBF2 | LMNA 966/4885L3MBTL1 2703/4885HPGD 610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.